ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för LY-2090314. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

18 träffar

Bibliografisk träff 2020-06-11

Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.

Fukuda K, Takeuchi S, Arai S, Kita K, Tanimoto A, Nishiyama A, Yano S.

Cancer Sci · research-article; journal article · DOI 10.1111/cas.14454

Bibliografisk träff 2020-06-01

Wnt Activation After Inhibition Restores Trabecular Meshwork Cells Toward a Normal Phenotype.

Dhamodaran K, Baidouri H, Sandoval L, Raghunathan V.

Invest Ophthalmol Vis Sci · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1167/iovs.61.6.30

Bibliografisk träff 2020-05-07

Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis.

Reggio A, Rosina M, Palma A, Cerquone Perpetuini A, Petrilli LL, Gargioli C, Fuoco C, Micarelli E, Giuliani G, Cerretani M, Bresciani A, Sacco F, Castagnoli L, Cesareni G.

Cell Death Differ · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41418-020-0551-y

Bibliografisk träff 2019-10-14

The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.

Mudgapalli N, Nallasamy P, Chava H, Chava S, Pathania AS, Gunda V, Gorantla S, Pandey MK, Gupta SC, Challagundla KB.

Mol Aspects Med · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1016/j.mam.2019.10.001

Bibliografisk träff 2019-09-27

Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer.

Santoro R, Zanotto M, Simionato F, Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F, Scarpa A, Melisi D.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-19-0270

Bibliografisk träff 2019-06-28

Berberine coated mannosylated liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3β pathway via upregulating miR-23a.

Sujitha S, Rasool M.

Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2019.105703

Bibliografisk träff 2018-05-11

Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M.

BMC Cancer · research-article; journal article · DOI 10.1186/s12885-018-4474-7

Bibliografisk träff 2018-03-29

Stress-induced phosphoprotein 1 acts as a scaffold protein for glycogen synthase kinase-3 beta-mediated phosphorylation of lysine-specific demethylase 1.

Tsai CL, Chao AS, Jung SM, Lin CY, Chao A, Wang TH.

Oncogenesis · research-article; journal article · DOI 10.1038/s41389-018-0040-z

Bibliografisk träff 2017-08-01

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.

Teicher BA, Silvers T, Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Parchment R, Krushkal J, Sonkin D, Rubinstein L, Morris J, Evans D.

Cancer Med · research-article; journal article · DOI 10.1002/cam4.1131

Bibliografisk träff 2017-07-22

Glycogen synthase kinase-3 inhibition sensitizes human induced pluripotent stem cells to thiol-containing antioxidants induced apoptosis.

Tu C, Xu R, Koleti M, Zoldan J.

Stem Cell Res · journal article · DOI 10.1016/j.scr.2017.07.019

Bibliografisk träff 2017-04-10

Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.

Nakata D, Koyama R, Nakayama K, Kitazawa S, Watanabe T, Hara T.

Prostate · journal article · DOI 10.1002/pros.23351

Bibliografisk träff 2016-03-04

Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.

Nisha CM, Kumar A, Vimal A, Bai BM, Pal D, Kumar A.

J Mol Graph Model · journal article · DOI 10.1016/j.jmgm.2016.03.001

Bibliografisk träff 2016-01-06

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.

Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, Wang X, Brail L, Borthakur G.

Leuk Lymphoma · clinical trial, phase ii; multicenter study; journal article · DOI 10.3109/10428194.2015.1122781

Bibliografisk träff 2015-09-25

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.

Gray JE, Infante JR, Brail LH, Simon GR, Cooksey JF, Jones SF, Farrington DL, Yeo A, Jackson KA, Chow KH, Zamek-Gliszczynski MJ, Burris HA.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-015-0278-7

Bibliografisk träff 2015-04-27

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.

Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, Engler TA, Chedid M.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0125028

Bibliografisk träff 2014-03-21

Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk.

Zamek-Gliszczynski MJ, Mohutsky MA, Rehmel JL, Ke AB.

Drug Metab Dispos · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1124/dmd.114.057018

Bibliografisk träff 2013-01-10

Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.

Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ, Cassidy KC.

Drug Metab Dispos · comparative study; multicenter study; clinical trial, phase i; journal article · DOI 10.1124/dmd.112.048488

Bibliografisk träff 2004-07-01

Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, Hawkins E, Iversen PW, Li Y, Lindstrom TD, Marquart AL, McLean J, Mendel D, Misener E, Briere D, O'Toole JC, Porter WJ, Queener S, Reel JK, Owens RA, Brier RA, Eessalu TE, Wagner JR, Campbell RM, Vaughn R.

J Med Chem · journal article · DOI 10.1021/jm049768a